© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Lipid Nanoparticles for Bioimaging and Drug Delivery Thomas Delmas 2009

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Outline Different types of Nanoparticles Our Nanoparticles: Lipid Nanoparticles (LNP) LNP for Drug Delivery: Drug encapsulation LNP for Biomedical Imaging: Contrast agent encapsulation Conclusion

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Different types of Nanoparticles Macromolecular assemblies: Micelles:Liposomes: Taille (nm) Nanospheres / Nanocapsules: Quantum Dots (Fluorescence): 2 to 10 nm Paramagnetic and Superparamagnetic Metal Oxide Nanoparticles (IRM): Gas Bubbles (echography): 10 to 500 nm 500 to 1000 nm Nanocarriers (for drug or contrast agent) Nanoparticulate Contrast Agents Our Lipid Nanoparticles

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Our Nanoparticles: Lipid Nanoparticles (LNP) Size: from 25 to more than 200nm Zeta Potential: slightly negative: -5 to -10mV Physical Stability: > 18 months Molecular label and/or Drug Lipid Nanoparticles (LNP): Emulsion of wax/oil in water stabilised by a mixture of surfactants E

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Fabrication procedure Fabrication procedure: simple, fast, and easy to translate to industry Nanoemulsion 2 phases mixing Ultrasonication Surfactant PEG Phospholipides Drug or Fluorophore Oil + Wax Oily phase Oil + Wax (10 % w/w) Phospholipides (6,9 % w/w) Drug or Fluorophore (< 0,04 % w/w) Aqueous phase Solution (69,2 % w/w) Surfactant PEG (11,4 % w/w) Glycerol (2,5 % w/w)

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 LNP as carriers for Contrast Agents and Drugs Principle: Encapsulate Active Pharmaceutical Ingredient (drug) or Contrast Agent (molecular or nanoparticular agent) Protect Target Improve efficiency Aims: of encapsulation for both approaches:

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Different locations for inclusion of molecular compounds Inclusion of lipophilic compounds within the NP core Inclusion of amphiphilic compounds within the NP surface (surfactant layer) Grafting of hydrophilic compounds onto the NP surface Different possibilities for inclusion of an imaging agent or a therapeutic drug

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Lipid Nanoparticles as Nanoparticulate carrier for Drug Delivery

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Outline Usual Active Pharmaceutical Ingredients (API) Limitations Principle of using Drug Delivery Systems (DDS) Effects on Pharmacocinetics Experimental Approach

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Usual Active Pharmaceutical Ingredients : Limitations Solubility issues Degradation issues Biodistribution issues: - low specificity/affinity for the pathological target site - Cross biological barriers (Blood Brain Barrier…) Very high API dose used to achieve suffifient local concentrations - Limited efficiency - Dramatic secondary effects /toxicity

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Exemple : Chemotherapy Aim: trigger cancer cells apoptosis (death) by using cytotoxic drugs Results: numerous efficient cytotoxic drugs but targeting issues… Low Therapeutic Index Limited efficiency (Therapeutic index curve) because of too many undesirable secondary effects

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 ‘Therapeutic Index’ Concept Concentration time Toxicity Limit (LT): Undesirable secondary effects on kidneys, liver… Therapeutic Index: (LT-LE) Efficiency Limit (LE): Lowest dose to achieve in order to obtain an effect Therapeutic use zone (curve type ‘oral absorption’)

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Principle: « Carry the drug to the target organ » P. Herlich (1906) Use of submicronic systems able of: (i) Molecule: protect degradation, improve solubility and biodisponibility (ii) Action approach: control the spatial and temporal release of the drug New Delivery approach: Drug Delivery Systems (DDS) Therapeutic Index increase by : - Decrease secondary effects / reduce toxicity - Increase available / used doses

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Effect of Drug Encapsulation on Pharmacocinetics Concentration time Toxicity Limit (LT) Therapeutic Index Efficiency Limit (LE) - Decrease of the systemic toxicity (Increase of Toxicity Limit) thanks to a better targeting - Possible efficiency increase (Diminution limite d’efficacité) thanks to a controlled release / better API internalisation - Efficiency increase by a prolonged release of the API (in time) (by staying longer in the zone of therapeutic use) : decrease in the number of API administration

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 New Delivery Approach: API Encapsulation Procedure: Simple carrier Stealth carrier Targeted stealth carrier - Simple carrier: Drug solubility and Protection + temporal release of the drug - Stealth carrier: Not recognised by immunological system: homogeny tissues distribution and prolonged blood transport + passive targeting (EPR effect) - Targeted stealth carrier: Active targeting: API spatial delivery Specific coating with hydrophilic polymer e.g. Polyethylene glycol (PEG)… Attachment of vector molecules e.g DNA, antibodies, peptides, saccharides

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 ‘EPR effect’: Enhanced Permeability and Retention effect - Enhanced permeability at tumour site: (extravasation) Increased blood vessels permeability because of tissues inflammation + constant angiogenesis - Low lymphatic drainage of tumours: (entrapment) High cellular density + low irrigation Non specific accumulation in tumours Passive targeting of nanoparticles tumour:

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Passive and Active Targeting Passive Targeting (EPR effect) Active Targeting (vectors molecules)

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 New Delivery Approach: Use of nanocarrier Advantages: API Encapsulation : - API protection against physicochemical and biological degradation - Solubilisation - Biodistribution modification - API release control - Efficiency improvement /Toxicity reduction Passive targeting, Active targeting: - Diminution of systemic concentration : secondary effects reduction - Possibility of increasing administered dose (and so, treatment efficiency)

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 DDS in vitro and in vivo efficiency Paclitaxel encapsulated in PLGA nanoparticles * Antitumor effect of Paclitaxel loaded nanoparticles: * Viability of Hela cells under Paclitaxel treatment: [ F. Danhier et al. / Journal of Controlled Release 133 (2009) 11–17 ]

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Lipid Nanoparticles as Nanoparticulate carrier for Biomedical Fluorescence Imaging

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Aims Protect: - from external media (pH, …) - the external media from contrast agent Target: - passive targeting (EPR effect) - active targeting (biomolecules attachment) Improve efficiency: - better fluorescence quantum yield - less photobleaching… Same as for Drug

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Principle Encapsulate fluorescent agent and keep it encapsulated for long Note: other contrast agents can be encapsulated, both molecular and nanoparticulate agents for fluorescence imaging, MNR, PET, US…

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Fluorescence Stability (PROTECT) Stable for pH 3-8 Degradation for basic conditions or highly acidic conditions Two different degradation kinetics: - Fast under basic conditions - Slow under acidic conditions As a function of time As a function of pH Very good stability for 3<pH<8

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Targeting cancer cells (TARGET) Active targeting with cycloRGD peptide: in cellulo study: HEK β3 cells (surexpression of integrines αvβ3, ligand of cRGD) LNP control LNP cRGD Recognition and specific internalisation

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 In vivo tumour Detection On mice: comparison passive / active targeting Mice 24 h post injectionContrast tumour/skin: Kinetic Mice organs 96h post injection Control (Passive targeting) RGD (Passive targeting + Active targeting) Control (Passive targeting) RGD (Passive targeting + Active targeting)

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Conclusion Protect, Target, Improve High interest of nanoparticulate systems for Contrast Agent and Drugs encapsulation: Protect, Target, Improve Lipid Nanoparticles (LNP) as efficient carrier: →Fluorophore: →Fluorophore: Stable encapsulation at stock and in vivo conditions → Drug: → Drug: stable encapsulation at stock conditions and release under in vivo conditions Some carriers already on the market, More to come…

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Innovation for industry Thank you for your attention Any questions? For more information :

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Supplementary information

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09 Imaging applications (fluorescence) Tumors Imaging Benefit of the formulation for dye passive accumulation in tumour 24h following IV injection in mice. cRGD functionalization of the formulations for  V  3 mediated active targeting of tumours. A, B: Specific labelling of HEK  3 cells by cRGD-LNP in comparison to non-functionalized LNP. C. In vivo tumour/skin fluorescence ratio raised due to the LNP cRGD- functionalization. AB C D A B Popliteal lymph node Lymph nodes Imaging Intradermal injection of ICG- doped formulations (A) or free ICG (B) in right hind leg of mouse.

© CEA Tous droits réservés. Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l’autorisation écrite préalable du CEA All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA Thomas Delmas – 16/04/09